FAM
Fred Alger Management Portfolio holdings
AUM
$22.3B
1-Year Return
57.87%
This Quarter Return
-8.4%
1 Year Return
+57.87%
3 Year Return
+264.72%
5 Year Return
+406.03%
10 Year Return
+1,631.73%
AUM
$22.8B
AUM Growth
-$4.41B
(-16%)
Cap. Flow
-$880M
Cap. Flow
% of AUM
-3.87%
Top 10 Holdings %
Top 10 Hldgs %
36.84%
Holding
614
New
135
Increased
158
Reduced
239
Closed
65
Top Buys
| 1 |
NVIDIA
NVDA
|
+$198M |
| 2 |
Netflix
NFLX
|
+$190M |
| 3 |
Lowe's Companies
LOW
|
+$147M |
| 4 |
Starbucks
SBUX
|
+$92.4M |
| 5 |
Novartis
NVS
|
+$85.4M |
Top Sells
| 1 |
Abbott
ABT
|
+$246M |
| 2 |
Microsoft
MSFT
|
+$199M |
| 3 |
Dollar Tree
DLTR
|
+$152M |
| 4 |
Salesforce
CRM
|
+$144M |
| 5 |
Adobe
ADBE
|
+$140M |
Sector Composition
| 1 | Technology | 33.16% |
| 2 | Healthcare | 22.78% |
| 3 | Consumer Discretionary | 14.09% |
| 4 | Communication Services | 9.78% |
| 5 | Financials | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DCPH
401
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $165K | ﹤0.01% |
4,000
-14,000
| -78% | -$578K |
|
|
TRIL
402
DELISTED
Trillium Therapeutics Inc.
TRIL
| $162K | ﹤0.01% |
+40,000
| New | +$162K |
|
403
Diamondback Energy
FANG
$39.5B
| $158K | ﹤0.01% |
+6,034
| New | +$158K |
|
404
Apellis Pharmaceuticals
APLS
$3.39B
| $134K | ﹤0.01% |
5,000
-10,000
| -67% | -$268K |
|
|
CBIO
405
Crescent Biopharma, Inc. Common Stock
CBIO
$174M
| $125K | ﹤0.01% |
550
-50
| -8% | -$11.4K |
|
406
PVH
PVH
$3.96B
| $122K | ﹤0.01% |
3,250
| – | – |
|
|
FPRX
407
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $114K | ﹤0.01% |
50,000
| – | – |
|
408
T Rowe Price
TROW
$23.5B
| $78K | ﹤0.01% |
797
+113
| +17% | +$11.1K |
|
409
Clearside Biomedical
CLSD
$26.6M
| $68K | ﹤0.01% |
40,000
+10,000
| +33% | +$17K |
|
410
Brown-Forman Class B
BF.B
$13B
| $66K | ﹤0.01% |
1,193
+723
| +154% | +$40K |
|
|
PRVB
411
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $64K | ﹤0.01% |
+7,000
| New | +$64K |
|
412
Marsh & McLennan
MMC
$99.2B
| $63K | ﹤0.01% |
731
+434
| +146% | +$37.4K |
|
413
McKesson
MCK
$87.8B
| $62K | ﹤0.01% |
458
+230
| +101% | +$31.1K |
|
414
Cue Biopharma
CUE
$59.2M
| $57K | ﹤0.01% |
+4,000
| New | +$57K |
|
415
iShares Russell 2000 Growth ETF
IWO
$12.6B
| $57K | ﹤0.01% |
363
-17,152
| -98% | -$2.69M |
|
416
Nordson
NDSN
$12.5B
| $56K | ﹤0.01% |
417
+323
| +344% | +$43.4K |
|
417
Trane Technologies
TT
$91.1B
| $53K | ﹤0.01% |
636
+142
| +29% | +$11.8K |
|
418
Crown Holdings
CCK
$11B
| $51K | ﹤0.01% |
877
-270
| -24% | -$15.7K |
|
419
Skyworks Solutions
SWKS
$11.1B
| $51K | ﹤0.01% |
566
-585
| -51% | -$52.7K |
|
420
Labcorp
LH
$23.1B
| $49K | ﹤0.01% |
450
+22
| +5% | +$2.4K |
|
421
Lockheed Martin
LMT
$107B
| $43K | ﹤0.01% |
127
+43
| +51% | +$14.6K |
|
422
Cassava Sciences
SAVA
$105M
| $41K | ﹤0.01% |
+10,000
| New | +$41K |
|
423
Carlisle Companies
CSL
$16.3B
| $37K | ﹤0.01% |
297
+93
| +46% | +$11.6K |
|
424
WIX.com
WIX
$9.3B
| $36K | ﹤0.01% |
355
-281
| -44% | -$28.5K |
|
425
CDW
CDW
$22.1B
| $32K | ﹤0.01% |
344
-7,312
| -96% | -$680K |
|